AbbVie Inc.

ABBV

Exchange: NYSE
Industry: Pharmaceutical Preparations
SEC CIK: 0001551152

SEC filings (opens in a new tab)

In the last 90 days, AbbVie Inc. insiders filed 0 open-market purchases and 1 sale; 4,238 institutions reported holding it in 13F filings for Q2 2026, worth $358.6B in total; superinvestors Gardner Russo & Quinn and Harris Associates (Oakmark) hold it.

Key figures

Insider buysOpen market, last 90 days: 0
Insider sellsLast 90 days, $8.18M in total: 1
13F holdersQ2 2026, +177 vs. previous quarter: 4,238
13F valueReported value at the end of Q2 2026: $358.6B
Superinvestors holdingAt the end of Q2 2026: 2

Price chart

Chart by TradingView (opens in a new tab)

Superinvestors holding ABBV, Q2 2026

2 superinvestors report holding AbbVie Inc. on Form 13F. Percentages are the stock's share of each portfolio.

Go to the superinvestors tab

Gardner Russo & Quinn

Tom Russo

<0.1%

AbbVie Inc.'s share of the portfolio

Shares: 12,410
Value: $3.12M

Harris Associates (Oakmark)

Bill Nygren

<0.1%

AbbVie Inc.'s share of the portfolio

Shares: 2,420
Value: $609.0K

Latest insider trades

Open-market purchases and sales by AbbVie Inc. insiders from Form 4, newest first.

See all insider trades

Insider trades
Filed (ET)	Trade date	Filing delay	Insider	Transaction	Shares	Avg price	Value	Holding change	Flags
Aug 18, 2026 (view filing)5:00 PM ET	Aug 14	4 days	Donoghoe NicholasEVP, CHIEF BUS/STRAT OFFICER	SSaleCommon Stock, $0.01 par value	−32.7K	$250.00	−$8.18M	−30.5%74.4K after
Mar 6, 2026 (view filing)	Mar 4	2 days	Purdue David RyanSVP, Controller	SSaleCommon Stock, $0.01 par value	−5.23K	$233.56	−$1.22M	−66.3%2.65K after
Mar 3, 2026 (view filing)	Mar 2	1 day	Siatis Perry CEVP, GC AND SECRETARY	SSaleCommon Stock, $0.01 par value	−18.7K	$234.39	−$4.38M	−80.2%4.62K after	3 lots10b5-1
Feb 27, 2026 (view filing)	Feb 25	2 days	Siatis Perry CEVP, GC AND SECRETARY	SSaleCommon Stock, $0.01 par value	−22.4K	$230.00	−$5.15M	−37.0%38.1K after	10b5-1
Aug 14, 2025 (view filing)	Aug 12	2 days	Saleki-Gerhardt AzitaEVP, CHIEF OPERATIONS OFFICER	SSaleCommon Stock, $0.01 par value	−42.4K	$198.42	−$8.41M	−19.3%177.3K after
Aug 7, 2025 (view filing)	Aug 5	2 days	Donoghoe NicholasEVP, CHIEF BUS/STRAT OFFICER	SSaleCommon Stock, $0.01 par value	−13.3K	$198.51	−$2.64M	−18.6%58.2K after	2 lots
Apr 2, 2025 (view filing)	Mar 31	2 days	Stewart Jeffrey RyanEVP, CHIEF COMMERCIAL OFFICER	SSaleCommon Stock, $0.01 par value	−58.8K	$210.08	−$12.4M	−52.5%53.2K after	2 lots
Mar 18, 2025 (view filing)	Mar 14	4 days	Reents Scott TEVP, CHIEF FINANCIAL OFFICER	SSaleCommon Stock, $0.01 par value	−17.6K	$212.34	−$3.75M	−60.4%11.6K after
Mar 4, 2025 (view filing)	Mar 3	1 day	Richmond Timothy J.EVP, CHIEF HR OFFICER	SSaleCommon stock, $0.01 par value	−21.3K	$210.45	−$4.47M	−77.6%6.13K after	3 lots10b5-1
Mar 4, 2025 (view filing)	Feb 28-Mar 3	4 days	Gonzalez Richard ADirector	SSaleCommon Stock, $0.01 par value	−98.6K	$205.45	−$20.3M	−20.2%388.9K after	2 lots

Top 10 13F holders, Q2 2026

The largest institutional positions in AbbVie Inc. at the end of Q2 2026; share changes are against Q1 2026.

See all 4,238 holders

Institutions holding ABBV in Q2 2026
Institution	Shares	Value	% of portfolio	Change in shares	Action
BlackRock, Inc.	149,488,412	$37.6B	0.56%	−1,209,713−0.8%	Reduced
Vanguard Capital Management LLC	115,396,098	$29.0B	0.62%	+515,774+0.4%	Added
Banque Cantonale Vaudoise	89,306	$22.5B	3.11%	−4,885−5.2%	Reduced
State Street Corp	82,596,748	$20.8B	0.61%	+1,379,232+1.7%	Added
Vanguard Portfolio Management LLC	48,477,996	$12.2B	0.55%	−1,045,082−2.1%	Reduced
JPMorgan Chase & Co	47,862,796	$12.2B	0.71%	−8,878,895−15.6%	Reduced
Geode Capital Management, LLC	46,998,433	$11.8B	0.63%	+260,852+0.6%	Added
Morgan Stanley	38,901,001	$9.79B	0.52%	+884,227+2.3%	Added
Capital Research Global Investors	30,101,551	$7.57B	1.06%	−1,153,235−3.7%	Reduced
Norges Bank	25,554,538	$6.43B	0.64%	+25,554,538	New